Fulltext Search
363 Sales as a Health Care M&A Tool, Part 2 - Pros and Cons for Buyers and Sellers

 

Over the summer, we wrote about why health care companies may want to consider buying assets out of bankruptcy, taking advantage of the Bankruptcy Code Section 363 sale process (a “363 Sale”). We are back with our second post, to provide more detail to the process and discuss some pros and cons of 363 Sales.

USA, Insolvency & Restructuring, Litigation, Mintz, Due diligence, Non-disclosure agreement, Title 11 of the US Code
363 Sales as a Health Care M&A Tool, Part 1 - Overview

This two-part blog series discusses why buyers looking to make strategic purchases in the health care industry might want to take advantage of the Bankruptcy Code Section 363 sale process (363 Sale) and the pros and cons of buying assets out of bankruptcy through a 363 Sale.

USA, Healthcare & Life Sciences, Insolvency & Restructuring, Mintz, Due diligence, Coronavirus
House Committee on Financial Services holds hearing on Lehman Bankruptcy examiner’s report

On April 20, the House Committee on Financial Services held a hearing to discuss public policy issues raised by last month’s report of court-appointed bankruptcy examiner for Lehman Brothers Holdings Inc. (Lehman Brothers), Mr. Anton R. Valukas. The Committee heard testimony from the following witnesses:

Panel One:

USA, Capital Markets, Insolvency & Restructuring, Alston & Bird LLP, Bankruptcy, Audit, Board of directors, Accounting, Defamation, Balance sheet, US Securities and Exchange Commission, Federal Reserve (USA), FSAB, US House Committee on Financial Services, Chair of the Federal Reserve, Lehman Brothers, Ernst & Young, Chief executive officer